Private Capital Advisors Inc. Increases Stake in Immunome, Inc. $IMNM

Private Capital Advisors Inc. increased its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 393.1% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 189,844 shares of the company's stock after purchasing an additional 151,343 shares during the period. Private Capital Advisors Inc. owned approximately 0.22% of Immunome worth $1,766,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in IMNM. Primecap Management Co. CA boosted its stake in shares of Immunome by 1,115.7% in the 1st quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company's stock valued at $22,974,000 after purchasing an additional 3,132,900 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Immunome by 37.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after buying an additional 2,054,640 shares during the last quarter. Vanguard Group Inc. raised its holdings in Immunome by 43.4% during the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after buying an additional 1,303,753 shares during the last quarter. Woodline Partners LP raised its holdings in Immunome by 69.0% in the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock worth $11,157,000 after purchasing an additional 676,804 shares in the last quarter. Finally, Driehaus Capital Management LLC bought a new position in Immunome in the 1st quarter worth $4,109,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Stock Performance

Shares of IMNM stock opened at $16.74 on Wednesday. Immunome, Inc. has a one year low of $5.15 and a one year high of $17.08. The company's 50-day moving average is $11.28 and its 200 day moving average is $9.66. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -5.44 and a beta of 1.94.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The company had revenue of $4.02 million for the quarter, compared to the consensus estimate of $1.03 million. As a group, research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Evercore ISI assumed coverage on shares of Immunome in a report on Friday, August 22nd. They issued an "outperform" rating and a $18.00 price objective for the company. Guggenheim reiterated a "buy" rating and issued a $25.00 price target on shares of Immunome in a research note on Monday, August 25th. Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They issued a "buy" rating and a $26.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a research note on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $23.20.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.